Abstract
Background Allergic diseases are characterized by tissue eosinophilic and basophilic inflammation. There is substantial evidence that this particular inflammatory profile results from the migration to tissues of a common eosinophil-basophil (Eo/B) progenitor that undergoes a differentiative process regulated by local cytokines, termed in situ hemopoiesis. We therefore investigated the role and mechanisms of TSLP involvement in human Eo/B in situ hemopoiesis in relation to atopy. Also, since candidate gene and genomewide association studies have identified ‘protective’ associations between the single nucleotide polymorphism (SNP) rs1837253 in the TSLP gene and risk for allergy, asthma and airway hyper-responsiveness, we evaluated the secretion of TSLP protein from primary nasal epithelial cells (NEC) in relation to rs1837253 genotype.
Highlights
Thymic Stromal Lymphopoietin (TSLP) promotes human eosinophil-basophil in situ hemopoieisis, and its secretion from human nasal epithelium is a function of TSLP genotype
Allergic diseases are characterized by tissue eosinophilic and basophilic inflammation
Since candidate gene and genomewide association studies have identified ‘protective’ associations between the single nucleotide polymorphism (SNP) rs1837253 in the TSLP gene and risk for allergy, asthma and airway hyper-responsiveness, we evaluated the secretion of TSLP protein from primary nasal epithelial cells (NEC) in relation to rs1837253 genotype
Summary
Thymic Stromal Lymphopoietin (TSLP) promotes human eosinophil-basophil in situ hemopoieisis, and its secretion from human nasal epithelium is a function of TSLP genotype. Judah Denburg1*, Claudia Hui, Helen Neighbour, Delia Heroux, Loubna Akhabir, Andrew Sandford. From The 10th Symposium of Experimental Rhinology and Immunology of the Nose (SERIN 2015) Stockholm, Sweden. From The 10th Symposium of Experimental Rhinology and Immunology of the Nose (SERIN 2015) Stockholm, Sweden. 19-21 February 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
